Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Clear all
Completed Not applicable Interventional Results available

Interactive Spaced Education to Optimize Hypertension Management

NCT00904007
View directory record Official record
Conditions
Hypertension
Interventions
Interactive Spaced Education (ISE) --- online education
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Brockton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 29, 2026, 4:24 AM EDT
Withdrawn Not applicable Interventional

Nutrition Optimization and Community Upliftment for Postpartum Recovery: Hypertension

NCT06445543
View directory record Official record
Conditions
Obesity, Maternal, Pre-Eclampsia; Complicating Pregnancy, Gestational Hypertension, Eclampsia; Complicating Pregnancy
Interventions
MFeast ENHANCED, MFeast Usual Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Not applicable Interventional

Acute Probiotic Supplementation and Endothelial Function

NCT04364074
View directory record Official record
Conditions
Coronary Artery Disease, Hypertension, Hyperlipidemias, Peripheral Vascular Diseases, Cerebral Arterial Diseases
Interventions
Goodbelly, Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

NCT02167035
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID)
Drug
Lead sponsor
Cornerstone Health Care, PA
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 29, 2026, 4:24 AM EDT
Withdrawn Not applicable Interventional

Lisinopril for Renal Protection in Postpartum Preeclamptic Women

NCT05016440
View directory record Official record
Conditions
Microalbuminuria, Preeclampsia
Interventions
Lisinopril
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 29, 2026, 4:24 AM EDT
Active, not recruiting Phase 3 Interventional

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

NCT05983250
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 29, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

NCT03068130
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
46
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 29, 2026, 4:24 AM EDT
Not yet recruiting Not applicable Interventional

Effect of Late Ripcord Removal From Glaucoma Drainage Device

NCT07803536
View directory record Official record
Conditions
GLAUCOMA 1, OPEN ANGLE, D (Disorder), Glaucoma
Interventions
Ripcord removal
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

NCT01176565
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Intravenous nicardipine hydrochloride
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 29, 2026, 4:24 AM EDT
Completed No phase listed Observational

Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.

NCT03778411
View directory record Official record
Conditions
Advanced Chronic Liver Disease, NASH
Interventions
VCTE with splenic stiffness measurement
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

NCT01218100
View directory record Official record
Conditions
Stage 2 Diastolic Hypertension
Interventions
nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 64 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
89
States / cities
Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Results available

BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF

NCT04434664
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Hypertension
Interventions
Amlodipine Besylate, Metoprolol Succinate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

NCT01491919
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril
Drug
Lead sponsor
Uptal Patel
Other
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Results available

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

NCT03078907
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 29, 2026, 4:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Genes That May Increase the Risk for Heart Disease in African Americans

NCT00344136
View directory record Official record
Conditions
Heart Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 95 Years
Enrollment
5,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325403
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years to 75 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Not applicable Interventional

Remote Physician Care for Home Hospital Patients

NCT04080570
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Remote Visit
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

NCT01303783
View directory record Official record
Conditions
Hypertension, Essential
Interventions
Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

NCT02371746
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
Drug
Lead sponsor
Envisia Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 29, 2026, 4:24 AM EDT
Withdrawn Not applicable Interventional

Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure

NCT00811486
View directory record Official record
Conditions
Right Heart Failure, Pulmonary Hypertension
Interventions
Spironolactone and conivaptan
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 29, 2026, 4:24 AM EDT
Terminated Not applicable Interventional

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

NCT00980031
View directory record Official record
Conditions
Myocardial Remodeling
Interventions
Eplerenone, Lactose Tablet
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 29, 2026, 4:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Exercise, Hypertension, and Gut Dysbiosis in African Americans

NCT03897777
View directory record Official record
Conditions
Hypertension
Interventions
Exercise Training effect on Hypertension and Gut Dysbiosis
Behavioral
Lead sponsor
North Carolina Agriculture & Technical State University
Other
Eligibility
30 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 29, 2026, 4:24 AM EDT
Completed Early Phase 1 Interventional

Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)

NCT02221830
View directory record Official record
Conditions
Preeclampsia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 29, 2026, 4:24 AM EDT
Completed No phase listed Observational Results available

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

NCT00716742
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 29, 2026, 4:24 AM EDT